July 30, 2022
Relatlimab and Nivolumab vs Nivolumab in Previously Untreated Metastatic/Unresectable Melanoma: Overall Survival and Response From RELATIVITY-047 BookmarkGeorge Lundberg, MD
According to MedPage Today, the addition of the drug relatlimab to treatment with nivolumab improved survival for people with advanced melanoma in a clinical trial.
September 18, 2018
Could Adding a TLR9 Agonist Improve Responses in Metastatic Melanoma? BookmarkEmma Shtivelman, PhD
Excerpt from Cancer Network:
“A phase I trial found promising activity and good tolerability with the combination of pembrolizumab and a stimulant of Toll-like receptor 9 (TLR9) known as SD-101 in patients with unresectable or metastatic melanoma, particularly in those who had not received prior anti–programmed death 1 (PD-1)/programmed death ligand 1 (PD-L1) therapy.
“PD-1/PD-L1 inhibition has improved outcomes in metastatic melanoma, and studies have indicated that combination therapy can increase immune responses further. “Despite the improvement in response rates with combination immunotherapy, a large unmet need remains,” wrote study authors led by Antoni Ribas, MD, PhD, of the University of California, Los Angeles, Jonsson Comprehensive Cancer Center.”
Go to full article published by Cancer Network on Sep 5, 2018.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.